Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting

Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 10, Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte Inc. (NASDAQ:PCVX). The update comes amid speculation regarding the potential effects on pneumococcal vaccine developers following the upcoming meeting of the Advisory Committee on Immunization Practices (ACIP).

Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting

Cantor Fitzgerald analyst Carter Gould explained the firm’s position on Vaxcyte Inc. (NASDAQ:PCVX), pointing out that the upcoming ACIP meeting is unlikely to focus much on pneumococcal disease. This implies that the meeting’s talks will have a direct impact on Vaxcyte’s operations or prospects. Gould also noted that the potential approval and ACIP recommendation of Vaxcyte’s vaccination efforts are still a few years away.

The analyst also highlighted the strength of the pneumococcal conjugate vaccine (PCV) data from Vaxcyte Inc. (NASDAQ:PCVX). Gould said that the robustness of this evidence makes a compelling case for sticking with tried-and-true vaccination practices.

A clinical-stage vaccine pioneer, Vaxcyte, Inc. (NASDAQ:PCVX) develops, refines, and produces high-fidelity vaccines. The company’s medications aim to prevent or cure bacterial illnesses such as Shigella, Group A Strep, invasive pneumococcal disease, and periodontitis.

While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.